Orchard Therapeutics plc American Depositary Shares
ORTX
ORTX was delisted on the 23rd of January, 2024.
48 hedge funds and large institutions have $16.5M invested in Orchard Therapeutics plc American Depositary Shares in 2022 Q4 according to their latest regulatory filings, with 8 funds opening new positions, 10 increasing their positions, 10 reducing their positions, and 5 closing their positions.
60% more first-time investments, than exits
New positions opened: 8 | Existing positions closed: 5
2% more funds holding
Funds holding: 47 → 48 (+1)
0% more repeat investments, than reductions
Existing positions increased: 10 | Existing positions reduced: 10
33% less capital invested
Capital invested by funds: $24.7M → $16.5M (-$8.22M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Mariner
Overland Park,
Kansas
|
+$279K |
| 2 |
Acadian Asset Management
Boston,
Massachusetts
|
+$46K |
| 3 |
FA
Forefront Analytics
West Conshohocken,
Pennsylvania
|
+$28.7K |
| 4 |
Jane Street
New York
|
+$13.1K |
| 5 |
Goldman Sachs
New York
|
+$8.94K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
DM
Deerfield Management
New York
|
-$1.67M |
| 2 |
BlackRock
New York
|
-$356K |
| 3 |
Renaissance Technologies
New York
|
-$306K |
| 4 |
Verition Fund Management
Greenwich,
Connecticut
|
-$25K |
| 5 |
Bank of America
Charlotte,
North Carolina
|
-$23.5K |
ORTX Hedge Fund Activity: Q4 2022 in Review
48 of the 6,237 institutional investors tracked by Wall St. Rank reported a position in Orchard Therapeutics plc American Depositary Shares (ORTX) for Q4 2022, worth a combined $16.5M — down 33% from $24.7M a quarter earlier.
Buyers outnumbered sellers: 8 funds opened new ORTX positions and 5 closed out — a net gain of 3 holders — while 10 added to existing stakes and 10 trimmed.
The largest buyer was Mariner, opening a new position worth an estimated $279K. The largest seller was Deerfield Management, cutting an estimated $1.67M.
- 48 institutional investors held Orchard Therapeutics plc American Depositary Shares (ORTX) as of Q4 2022, up from 47 in Q3 2022.
- Funds reported $16.5M of Orchard Therapeutics plc American Depositary Shares stock for Q4 2022, down 33% quarter-over-quarter.
- 8 funds opened new Orchard Therapeutics plc American Depositary Shares positions in Q4 2022 and 5 closed out, a net change of +3 holders.
- The largest Orchard Therapeutics plc American Depositary Shares buyer in Q4 2022 was Mariner, an estimated $279K added.
- The largest Orchard Therapeutics plc American Depositary Shares seller in Q4 2022 was Deerfield Management, an estimated $1.67M sold.
Based on aggregated 13F filings for Q4 2022.